EUCTR2007-001943-23-NL进行中（未招募）不适用
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - CILAB
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) with locally advanced (T4b) or metastatic (lymph node or visceral) urothelial tract or bladder cancer.
- •- ECOG Performans Status < or = 1
- •- No prior palliative chemotherapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Age < 18 years old.
- •- Disease localized only to the radiation fields without radiologically confirmed progression of the disease within the radiation fields after completion of prior radiotherapy.
- •PRIOR THERAPY:
- •-- Time (Neo)Adjuvant chemotherapy if < 6 months between end of (Neo)adjuvant chemotherapy and relapse
- •- Less than 6 weeks or 3 weeks respectively from prior radiotherapy or surgery to time of randomization. Patients pN+ with no residual disease after surgery are not eligible.
- •- Less than 6 weeks elapsed from prior radiotherapy (in case of palliative radiotherapy for pain or bleeding control 6-week interval is not mandatory providing the patient recovered from all toxicities) and less than 3 weeks from surgery to time of randomization. Patients pN+ with no residual disease after surgery are not eligible
- •- Treatment with an investigational agent within 4 weeks (6 weeks for immunotherapy) of study enrollment
- •BIOLOGICAL CRITERIA: - Bone marrow function as defined by absolute neutrophil count < 1.5 x 10e9/L, platelet < 75 x10e9/L, or hemoglobin < 9.0 g/dL.
- •- Alkaline phosphatase (AP) = 2.5 x UNL associated with AST/ALT > 2.5 x UNL, or AP > 2.5 x UNL and = 5.0 x UNL associated with AST/ALT > 1.5 UNL or AP > 5.0 x UNL
- •- Total Bilirubin > 1.0 x UNL - Creatinine > ou = 1.0 x UNL, or actual creatinine clearance < 60 ml/min if creatinine > 1.0 x UNL and < ou = 1.5 UNL
- •PAST or CURRENT HISTORY
- •- Symptomatic History or new evidence of brain metastases or leptomeningeal disease (...)
- •- History of another neoplasm. Patients with prior history of either non-metastatic non-melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery, small field radiation or chemotherapy = 5 years prior to randomization, or treated patients with incidental protsate cancer (pT2, Gleason <=6), and PSA <+ 0.5 ng/ml at study entry will be eligible
- •- Prior cisplatin as (neo)adjuvant chemotherapy with cumulative dose> 300 mg/m² - Peripheral neuropathy > grade 1
- •- History of inflammatory bowel disease, significant bowel obstruction.
- •- History of hypersensitivity to platinum, gemcitabine, taxanes, polysorbate 80, or to compounds with similar chemical structures.
- •- Known human immunodeficiency virus (HIV) infection immunodeficiency-syndrome (AIDS)-related illness.
- •- Any other as active illness such as active uncontrolled infections, uncontrolled cardiac disease or hypertension, uncontrolled diabetes that would preclude safe administration of study therapy at the time of randomization (...)
- •CONCOMITANT TREATMENT
- •- Concurrent treatment with strong inhibitors of CYP P450 3A4 or patients planning to receive these treatments. For patients who were receiving treatment with such agents, a one-week washout period is required prior to randomization
- •- Concurrent treatment with strong inhibitors of cytochrome P450 2C8 (gemfibrozile) or patients planning to receive this treatment. For patients who were receiving treatment with such agent, a one-week washout period is required prior to randomization.
- •Others Refer to the Protocol.
研究者
相似试验
Unknown
3 期
arotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (CILAB)CTRI/2008/091/000036Sanofi Synthelabo India Limited900
进行中（未招募）
不适用
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer - CILABocally Advanced/Metastatic Urothelial Tract or Bladder CancerMedDRA version: 11.1Level: LLTClassification code 10005003Term: <Manually entered code. Term in E.1.1>EUCTR2007-001943-23-DEsanofi-aventis recherche & développement900
进行中（未招募）
不适用
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - CILABocally Advanced/Metastatic Urothelial Tract or Bladder CancerMedDRA version: 9.1Level: LLTClassification code 10005003Term: Bladder cancerEUCTR2007-001943-23-ITSanofi-Aventis Recherche et De'veloppement900
进行中（未招募）
1 期
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - CILABocally Advanced/Metastatic Urothelial Tract or Bladder CancerMedDRA version: 9.1Level: LLTClassification code 10005003Term: Bladder cancerEUCTR2007-001943-23-FRSanofi-Aventis Recherche et Développement900
进行中（未招募）
1 期
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer.------------------------------------------------------------------------------------------------------Estudio aleatorizado de LAROTAXEL + Cisplatino (LC) versus Gemcitabina + Cisplatino (GC) en el tratamiento de primera línea de cáncer del tracto urotelial o vejiga localmente avanzado / metastásico. - CILABocally Advanced/Metastatic Urothelial Tract or Bladder Cancer.---------------------------------------------------------------------------------cáncer del tracto urotelial o vejiga localmente avanzado / metastásicoMedDRA version: 9.1Level: LLTClassification code 10005003Term: Bladder cancerEUCTR2007-001943-23-ESSanofi-Aventis Recherche et Développement900